Loss of CDK7 activity either through genetic inhibition or through treatment with THZ1, a small-molecule covalent inhibitor, leads to a loss of recruitment of MED1 to the chromatin, loss of AR-target gene expression, increased apoptosis, reduced cell proliferation, and inhibition of tumor growth in mouse xenograft CRPC models. This evidence concerns the gene AR and neoplasm.